Why NervGen Pharma Corp.’s (NGEN) Stock Is Up 6.31%
As of Monday, July 13, NervGen Pharma Corp.’s NGEN share price has surged by 6.31%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 5.97%
As of Wednesday, July 08, NervGen Pharma Corp.’s NGEN share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why NervGen Pharma Corp.’s (NGEN) Stock Is Up 5.35%
As of Monday, June 29, NervGen Pharma Corp.’s NGEN share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 6.22%
As of Friday, June 05, NervGen Pharma Corp.’s NGEN share price has dipped by 6.22%, which has investors questioning if this is right time to buy.Michael Rose
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 43.48%
As of Friday, May 22, NervGen Pharma Corp.’s NGEN share price has dipped by 43.48%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $180.9 | $620.4 | 26% |
|
| Shares Out (Mil) | 57.9 | 43.1 | 51% |
|
| Institutional Ownership | 68.5% | 84.4% | 42% |
|
| Float (Mil) | 94.3 | 47.1 | 60% |
|
| Beta | 0.69 | 0.64 | 40% |
|
| Avg Daily Volume (000s) | 346 | 304 | 52% |
|
| Price Change (52-week) |
(24.7%) | 67.3% | 26% |
|
| Growth | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (29.6%) | (1.4%) | 14% |
|
| EPS (5yr) | (10.3%) | 14.9% | 21 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 7.0% | (14.9%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.067) | ($0.265) | ($0.316) | |
| Month Ago EPS | ($0.066) | ($0.262) | ($0.380) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.066) | ($0.289) | ($0.380) | |
| Year/Year Chg | 1.5% | (40.4%) | (52.4%) | |
| Financials | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($30) | ($11) | 21% |
|
| EPS (TTM) | ($0.402) | ($0.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($6) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $4 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $225 | $466 | 28% |
|
| Valuation | NGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 34.00 | 2.92 | 98% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.8% | na |
|
| Net Margin | na | 0.2% | na |
|
| ROA | (231.5%) | (21.5%) | 2% |
|
| ROE | na | (16.0%) | na |
|
| Liabilities to Assets | 73.3% | 34.8% | 69% |
|
| F-Score | 2 | 3 | 7% |
|
NervGen Pharma Corp. did not pass any screens on 8/7/2026.
